The pharmaceutical industry's embrace of artificial intelligence has reached a symbolic milestone: according to Drug Target Review, the first drug designed with AI assistance — called Rentosertib — has received an official name from the United States Adopted Names Council, marking a concrete step from hype toward reality.
Major drug companies are racing to lock in AI partnerships. Pfizer has signed a licensing agreement with startup Chai to access its newly released Chai-3 model, making Pfizer one of the first pharmaceutical companies to use the tool, according to MSN. Separately, Novo Nordisk is deploying generative AI powered by Anthropic and AWS, according to Amazon Web Services.
The Economist describes an "AI revolution in drugmaking" as already underway, and separately forecasts that AI will meaningfully accelerate drug development through 2025. According to drugdiscoverytrends.com, AI is already improving clinical trial success rates — one of the costliest bottlenecks in bringing new medicines to market.
Not everyone is satisfied with the pace. WIRED poses a pointed question — "Where Are All the AI Drugs?" — underscoring that most AI-designed molecules remain years away from patients.
The technology is also unlocking unexpected territory. According to Gavi, the Vaccine Alliance, AI tools are now being used to scan Africa's traditional natural remedies for overlooked drug candidates, potentially broadening the global medicine pipeline.
Institutions are preparing for a lasting shift. The University of Maryland's School of Pharmacy has launched a new Master's program in AI for Drug Development, while Business Insider reports that pharmaceutical companies are actively upskilling their workforces. Experts at Drug Target Review and law firm A&O Shearman caution that unresolved issues around data bias, transparency, and data provenance could slow progress if left unaddressed.
If AI can compress drug development timelines from decades to years, the result could be cheaper, faster medicines for diseases that currently have no good treatment options — but the gap between laboratory promise and approved drugs remains formidable.